RecruitingNot ApplicableNCT06472570

Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours

Escalating a Biological Dose of Radiation in the Target Volume Applying Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology

Enrollment

80 participants

Start Date

Oct 26, 2019

Study Type

INTERVENTIONAL

Conditions

Head and Neck Cancer

Summary

The goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with H\&N tumours.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a highly precise form of radiation therapy called stereotactic radiosurgery for people with tumors in the head and neck region. Unlike standard radiation that treats a large area, this approach targets tumors with pinpoint accuracy, potentially reducing damage to surrounding healthy tissue. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with a cancer in the head or neck area (such as squamous cell carcinoma, adenoid cystic carcinoma, sarcoma, or other types) - You have a non-cancerous tumor in the head or neck (such as paraganglioma) requiring radiation - You are generally able to carry out daily activities (not severely debilitated) - You are able to give informed consent **You may NOT be eligible if...** - You have uncontrolled (poorly managed) diabetes - You had a heart attack within the last 6 months - You are pregnant - You have a mental disorder that prevents you from giving informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONStereotactic radiotherapy boost

A stereotactic radiosurgery boost is given in two cases: * Upfront boost-on the first day of overall treatment time (OTT) (to 6 days before beginning conventional radiotherapy). * Direct boost-on Days 43-49 of OTT in relation to conventional radiotherapy to total dose (TD) 70 Gy, i.e., up to 6 days after a dose of 60 Gy. Treatment is conducted as radiotherapy alone or radiochemotherapy based on cisplatin 100 mg/m2 or 40 mg/m2 in a 21-day or 7-day cycle, respectively Patients who start the treatment from induction chemotherapy may have a chance to qualify for an upfront or direct boost, depending the evaluation of the response to systemic treatment Prescribed doses of stereotactic boost are in the range of 10-18 Gy